Drug intelligence / Profile preview

Bifidobacterium longum BB536 + Bifidobacterium infantis M-63 + Bifidobacterium breve M-16V

Development stage: Unknown
Lead developer: University of Campania Luigi Vanvitelli
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

A probiotic mixture developed by the University of Campania Luigi Vanvitelli for the treatment of seasonal allergic rhinitis in children. The active ingredient is a combination of three specific Bifidobacterium strains: *Bifidobacterium longum* BB536, *Bifidobacterium infantis* M-63, and *Bifidobacterium breve* M-16V. This product functions as a biologic with anti-inflammatory and immune-modulatory properties, specifically targeting IgE-mediated inflammatory reactions associated with allergic rhinitis. A Phase 3 trial (NCT02807064) in children aged 4-17 demonstrated that daily administration for eight weeks significantly improved allergic rhinitis symptoms and quality of life compared to placebo. It is formulated as a powder in sachets and has been marketed as a Class I medical device.

Other names: bifidobacteria-University of Campania Luigi Vanvitelli

Beyond the preview

Go deeper on Bifidobacterium longum BB536 + Bifidobacterium infantis M-63 + Bifidobacterium breve M-16V.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium longum BB536 + Bifidobacterium infantis M-63 + Bifidobacterium breve M-16V.

Explore the full profile